REFERENCES
1. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.
2. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
3. Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691-700.
4. Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab. 2021;33:21-32.
5. Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21:236-47.
6. Lee MH, Nuccio SP, Mohanty I, et al. How bile acids and the microbiota interact to shape host immunity. Nat Rev Immunol. 2024;24:798-809.
8. Foley MH, Walker ME, Stewart AK, et al. Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut. Nat Microbiol. 2023;8:611-28.
9. Jia B, Park D, Hahn Y, Jeon CO. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. Gut Microbes. 2020;11:1300-13.
10. Sun L, Zhang Y, Cai J, et al. Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer. Nat Commun. 2023;14:755.
11. Smirnova E, Muthiah MD, Narayan N, et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. Hepatology. 2022;76:1811-24.
12. Begley M, Hill C, Gahan CGM. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72:1729-38.
13. Xu F, Hu XJ, Singh W, Geng W, Tikhonova IG, Lin J. The complex structure of bile salt hydrolase from Lactobacillus salivarius reveals the structural basis of substrate specificity. Sci Rep. 2019;9:12438.
14. Rimal B, Collins SL, Tanes CE, et al. Bile salt hydrolase catalyses formation of amine-conjugated bile acids. Nature. 2024;626:859-63.
15. Bustos AY, de Valdez GF, Fadda S, Taranto MP. New insights into bacterial bile resistance mechanisms: the role of bile salt hydrolase and its impact on human health. Food Res Int. 2018;112:250-62.
16. Song Z, Cai Y, Lao X, et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome. 2019;7:9.
17. Zhong XC, Liu YM, Gao XX, et al. Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. Acta Pharmacol Sin. 2023;44:145-56.
18. Zhao Q, Dai MY, Huang RY, et al. Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice. Nat Commun. 2023;14:1829.
19. Liu X, Li J, Shi M, et al. Melatonin improves cholestatic liver disease via the gut-liver axis. J Pineal Res. 2024;76:e12929.
20. Wan Y, Yuan J, Li J, et al. Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: a 6-month randomized controlled-feeding trial. Clin Nutr. 2020;39:395-404.
21. Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-91.
22. He X, Gao X, Hong Y, et al. High fat diet and high sucrose intake divergently induce dysregulation of glucose homeostasis through distinct gut microbiota-derived bile acid metabolism in mice. J Agric Food Chem. 2024;72:230-44.
23. Parasar B, Zhou H, Xiao X, Shi Q, Brito IL, Chang PV. Chemoproteomic profiling of gut microbiota-associated bile salt hydrolase activity. ACS Cent Sci. 2019;5:867-73.
24. Khodakivskyi PV, Lauber CL, Yevtodiyenko A, et al. Noninvasive imaging and quantification of bile salt hydrolase activity: from bacteria to humans. Sci Adv. 2021;7:eaaz9857.
25. Yu J, Zhang H, Chen L, Ruan Y, Chen Y, Liu Q. Disease-associated gut microbiota reduces the profile of secondary bile acids in pediatric nonalcoholic fatty liver disease. Front Cell Infect Microbiol. 2021;11:698852.
26. Li Y, Wang H, He X, et al. Zhi-Kang-Yin formula attenuates high-fat diet-induced metabolic disorders through modulating gut microbiota-bile acids axis in mice. Chin Med. 2024;19:145.
27. Jia W, Rajani C, Zheng X, Jia W. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. J Mol Cell Biol. 2021;13:460-2.
28. Zhao WW, Xiao M, Wu X, et al. Ilexsaponin A1 Ameliorates diet-induced nonalcoholic fatty liver disease by regulating bile acid metabolism in mice. Front Pharmacol. 2021;12:771976.
29. Xu H, Yuan M, Niu K, et al. Involvement of bile acid metabolism and gut microbiota in the amelioration of experimental metabolism-associated fatty liver disease by nobiletin. Molecules. 2024;29:976.
30. Li X, Zhao W, Xiao M, et al. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. J Ethnopharmacol. 2022;294:115333.
31. Li DK, Chaudhari SN, Lee Y, et al. Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury. Sci Adv. 2022;8:eabo2794.
32. Li ZM, Kong CY, Mao YQ, et al. Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis. Pharmacol Res. 2023;196:106902.
33. Gao X, Lin X, Xin Y, et al. Dietary cholesterol drives the development of nonalcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice. J Nutr Biochem. 2023;117:109347.
34. Zhuge A, Li S, Yuan Y, et al. Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. Redox Biol. 2023;59:102582.
35. Shen B, Zhou C, Gu T, et al. Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis. Front Pharmacol. 2022;13:1080226.
36. Takimoto Y, Chu PS, Nakamoto N, et al. Myeloid TLR4 signaling promotes post-injury withdrawal resolution of murine liver fibrosis. iScience. 2023;26:106220.
37. Liu Y, Chen K, Li F, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology. 2020;71:2050-66.
38. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59-64.
39. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 2018;109:418-28.
40. Fogelson KA, Dorrestein PC, Zarrinpar A, Knight R. The gut microbial bile acid modulation and its relevance to digestive health and diseases. Gastroenterology. 2023;164:1069-85.
41. Chen ML, Yi L, Zhang Y, et al. Resveratrol attenuates trimethylamine- N -oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. mBio. 2016;7:e02210-15.
42. Pontes KSDS, Guedes MR, Cunha MRD, et al. Effects of probiotics on body adiposity and cardiovascular risk markers in individuals with overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2021;40:4915-31.
43. Agolino G, Pino A, Vaccalluzzo A, et al. Bile salt hydrolase: the complexity behind its mechanism in relation to lowering-cholesterol lactobacilli probiotics. J Funct Foods. 2024; 120:106357.
44. Kumar R, Grover S, Batish VK. Bile salt hydrolase (Bsh) activity screening of lactobacilli: in vitro selection of indigenous lactobacillus strains with potential bile salt hydrolysing and cholesterol-lowering ability. Probiotics Antimicro Prot. 2012;4:162-72.
45. Yang Y, Liu Y, Zhou S, Huang L, Chen Y, Huan H. Bile salt hydrolase can improve Lactobacillus plantarum survival in gastrointestinal tract by enhancing their adhesion ability. FEMS Microbiol Lett. 2019;366:fnz100.
46. Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384.
47. Huang F, Zheng X, Ma X, et al. Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat Commun. 2019;10:4971.
48. Liang C, Zhou XH, Gong PM, et al.
49. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408-18.
50. Zhang H, Dong M, Liu X. Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. Exp Ther Med. 2021;22:991.
51. Münzker J, Haase N, Till A, et al. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity. Microbiome. 2022;10:96.
52. Zhang J, Zhou J, He Z, et al. Salidroside attenuates NASH through regulating bile acid-FXR/TGR5 signaling pathway via targeting gut microbiota. Int J Biol Macromol. 2025;307:142276.
53. Sun H, Guo Y, Wang H, et al. Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis. Gut. 2023;72:1664-77.
54. Gong Z, Zhou J, Zhao S, et al. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. Oncotarget. ;7:83951-63.
55. Yue H, Li Y, Cai W, Bai X, Dong P, Wang J. Antarctic krill peptide alleviates liver fibrosis via downregulating the secondary bile acid mediated NLRP3 signaling pathway. Food Funct. 2022;13:7740-9.
56. Sun X, Chen Z, Yu L, et al. Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway. Front Pharmacol. 2023;14:1205323.
57. Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67:534-48.
58. Liu C, Du MX, Abuduaini R, et al. Enlightening the taxonomy darkness of human gut microbiomes with a cultured biobank. Microbiome. 2021;9:119.
59. Abu-Ali GS, Mehta RS, Lloyd-Price J, et al. Metatranscriptome of human faecal microbial communities in a cohort of adult men. Nat Microbiol. 2018;3:356-66.
